Wilbert van Duijnhoven
Overview
Explore the profile of Wilbert van Duijnhoven including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
9
Citations
265
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Langley J, Nolan T, Ramet M, Richmond P, Rosario Filho N, Haazen W, et al.
Open Forum Infect Dis
. 2024 Sep;
11(9):ofae453.
PMID: 39220658
Background: Respiratory syncytial virus (RSV) causes serious illness in children. The Ad26.RSV.preF vaccine candidate was immunogenic with acceptable safety in a phase 1/2a study of RSV-seropositive children. Here, we assessed...
2.
Leopold L, Vingerhoets J, Deleu S, Nalpas C, Weber K, van Dromme I, et al.
J Infect Dis
. 2024 Aug;
231(1):e132-e143.
PMID: 39172627
Background: An unmet need exists for effective antivirals to treat patients hospitalized with influenza. The results of 2 phase 3 studies that evaluated the efficacy and safety of pimodivir in...
3.
Vingerhoets J, van Dromme I, van Duijnhoven W, Anderson D, De Meyer S, Leopold L
Antivir Ther
. 2023 May;
28(3):13596535231174273.
PMID: 37226302
Background: Pimodivir is a first-in-class polymerase basic protein 2 (PB2) subunit inhibitor of the influenza A polymerase complex. The randomized double-blinded placebo-controlled phase 2b TOPAZ study demonstrated antiviral activity and...
4.
van Duijnhoven W, van Dromme I, Haesendonckx S, Witek J, Leopold L
Contemp Clin Trials
. 2022 Oct;
123:106952.
PMID: 36202198
Background: Currently, no single best primary endpoint exists for measuring the efficacy of treatments in seriously ill patients with respiratory infections, such as influenza, who require hospitalization. The Hospital Recovery...
5.
ONeil B, Ison M, Hallouin-Bernard M, Nilsson A, Torres A, Wilburn J, et al.
J Infect Dis
. 2020 Jul;
226(1):109-118.
PMID: 32604406
Background: Both the elderly and individuals with comorbidities are at increased risk of developing influenza-related complications. Novel influenza antivirals are required, given limitations of current drugs (eg, resistance emergence and...
6.
Finberg R, Lanno R, Anderson D, Fleischhackl R, van Duijnhoven W, Kauffman R, et al.
J Infect Dis
. 2018 Nov;
219(7):1026-1034.
PMID: 30428049
Background: Pimodivir, a first-in-class inhibitor of influenza virus polymerase basic protein 2, is being developed for hospitalized and high-risk patients with influenza A. Methods: In this double-blinded phase 2b study,...
7.
Milligan I, Gibani M, Sewell R, Clutterbuck E, Campbell D, Plested E, et al.
JAMA
. 2016 Apr;
315(15):1610-23.
PMID: 27092831
Importance: Developing effective vaccines against Ebola virus is a global priority. Objective: To evaluate an adenovirus type 26 vector vaccine encoding Ebola glycoprotein (Ad26.ZEBOV) and a modified vaccinia Ankara vector...
8.
Heldens J, Hulskotte E, Voeten T, Breedveld B, Verweij P, van Duijnhoven W, et al.
Vaccine
. 2014 May;
32(39):5118-24.
PMID: 24858566
Live attenuated influenza vaccine (LAIV) offers the promise of inducing a variety of immune responses thereby conferring protection to circulating field strains. LAIVs are based on cold adapted and temperature...
9.
Szegedi A, Verweij P, van Duijnhoven W, Mackle M, Cazorla P, Fennema H
J Clin Psychiatry
. 2013 Jan;
73(12):1533-40.
PMID: 23290326
Context: Asenapine is an approved treatment for schizophrenia in the United States. Objective: Meta-analyses were conducted to evaluate the efficacy of asenapine in acute schizophrenia compared with placebo and other...